Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study

Abstract Purpose The antibody–drug conjugate trastuzumab deruxtecan has proven to be not only efficient in patients with HER2+ breast cancers (BC), but also in those patients with so-called HER2-low BC. HER2-low tumors are well described in the general BC population, but not in patients with invasiv...

Cijeli opis

Bibliografski detalji

Glavni autori:	Karen Van Baelen, Ha-Linh Nguyen, François Richard, Gitte Zels, Maria Margarete Karsten, Guilherme Nader-Marta, Peter Vermeulen, Luc Dirix, Adam David Dordevic, Evandro de Azambuja, Denis Larsimont, Marion Maetens, Elia Biganzoli, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Patrick Neven, Giuseppe Floris, Christine Desmedt
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2025-06-01
Serija:	Breast Cancer Research
Teme:	Invasive lobular carcinoma HER2-low Clinicopathological features Survival
Online pristup:	https://doi.org/10.1186/s13058-025-02058-x
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!